Tumor-stroma proportion on primary tumor as a prognostic biomarker in advanced ovarian cancer patients receiving chemo-immunotherapy as first-line therapy: analyses from the NeoPembrOV/GINECO phase II randomized trial.

Auteurs

Collet L, Noël JC, Catteau X, Ardin M, Berthet J, Ghamry-Barrin S, Treilleux I, Bengrine Lefevre L, Martinez M, Rothé F, Sotiriou C, Caux C, Dubois B, Ray-Coquard I, Le Saux O

  • Date de publication

    June 2025

  • Type

    Article

  • Review

    ESMO Open

  • Researcher's name

    SOTIRIOU CHRISTOS

  • Hôpital

    Institut Jules Bordet

  • Service

    Médecine Oncologique

  • PMID

    40472658

  • DOI

    10.1016/j.esmoop.2025.105104